ClinicalTrials.gg
CompletedNCT06236893Updated May 31, 2025

Randomized, Double-Blind Placebo-Controlled Trial to Assess Overall User Experience of a Synbiotic Vaginal Suppository

An interventional study of VH-01 vaginal suppository tablet and Placebo vaginal suppository tablet in Vaginal Personal Care, sponsored by Seed Health. Completed at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-31.

Sponsored by Seed Health · Not applicable, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 10 studies in Vaginal Discharge with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Vaginal Discharge · United States.

Enrollment
3rd of 10
200 · median 91
Started
2024
with 1 other
No phase
7 of 10
1 open now
Registered
7th of 10
by date
Lead sponsor
1 of 10
Seed Health

Among the 10 studies in Vaginal Discharge with a site in United States, this one is the 3rd largest by enrollment, is one of 2 that started in 2024, is one of 7 with no phase, and was the 7th registered.

Vaginal Discharge

21 studies on the registry are indexed under Vaginal Discharge; 2 are open to participants now.

Browse Vaginal Discharge studies →

Open to participants now

1 of the 10 studies in Vaginal Discharge with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1 Vaginal Discharge study recruiting now, 1 sets no upper age limit and none stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Vaginal Discharge with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess the impact of a personal care product on vaginal health in individuals with a self-reported history of vaginal discomforts such as malodor, bothersome discharge, itching, irritation, and dryness. The personal care product, VH-01 contains a prebiotic and three distinct strains of Lactobacillus crispatus, a microbe commonly found in healthy vaginal microbiomes. The study will be a randomized, placebo-controlled trial where the test product will be compared to a placebo in a 2:1 manner. Participants will be asked to complete online questionnaires and provide vaginal samples to assess microbial communities.

The aims of this study are to assess:

  1. The user experience and acceptability of VH-01 vaginal suppository vs. placebo.
  2. Attitudes and perceptions of VH-01 vaginal suppository usage vs. placebo.
  3. Health-related quality of life during the use of VH-01 vaginal suppository vs. placebo.
  4. Changes in self-perceived vaginal discomforts during the use of VH-01 vaginal suppository vs. placebo.
Read the detailed description

The vaginal microbiome is a community of microorganisms that live inside of the vagina. Studies have shown that vaginal microbiomes can be classified into one of five community state types (CSTs) known as: CST I, II, III, IV, and V. CSTs are determined based on the taxonomic composition of the vaginal microbiome. CST I, dominated by Lactobacillus crispatus, is considered optimal and is significantly associated with vaginal health.

Lactobacillus crispatus produces lactic acid and other compounds that maintain an optimal vaginal pH, which discourages the growth of harmful microbes that lead to disruptions in the vaginal microbial ecosystem. These disruptions may increase vaginal discomforts such as vaginal malodor, discharge, itching, irritation, and dryness.

VH-01 is a multi-strain vaginal synbiotic designed to seed and sustain an optimal and protective CST I vaginal ecology. The product delivers an ecology of complimentary Lactobacillus crispatus and synbiotic ingredients to promote an optimal vaginal ecology. The strains were selected to confer maximal vaginal microbiome stability in response to potential perturbations such as menstruation, sex, exercise, medication and other environmental influences.

The purpose of this study is to determine whether vaginal health can be influenced by a novel personal care product comprised of a prebiotic, and multiple strains of Lactobacillus crispatus associated with a stable vaginal microbiome.

03

Conditions studied

  • Vaginal Personal Care

Browse trials for

Keywords

  • Lactobacillus crispatus
  • vaginal malodor
  • vaginal discharge
  • vaginal itching
  • vaginal irritation
  • vaginal dryness
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals with a vagina 18 - 55 years old at time of electronic consent
  • Sex assigned female at birth
  • Self-reported history of any of the following vaginal discomforts occurring recently and regularly, including but not limited to: Vaginal malodor, Bothersome vaginal discharge, Vaginal itching, Vaginal irritation, Vaginal dryness
  • Willing to use an intra-vaginal suppository during the study and not knowing the product identity (active or placebo)
  • Willing to complete questionnaires, which include questions related to vaginal health and sexual history/behavior
  • Able to read and comprehend English and provide written
  • Have reliable access to the internet

Exclusion criteria

Exclusion Criteria:

  • In menopause or experiencing menopausal symptoms
  • History of irregular menses; defined as less than 25 day or more than 35 day cycle or length of time between cycles varies by more than 9 days
  • Planned insertion or replacement of IUD in next 3 months (if applicable)
  • Active pelvic or vaginal infection (i.e., active urinary tract infection, active bacterial vaginosis, active yeast infection). NOTE: Eligible to re-screen 4 weeks after completion of treatment for an active infection.
  • Current or anticipated oral or vaginal antibiotic/antifungal treatment in the next 3 months (e.g., preoperative antibiotics for upcoming elective procedure). NOTE: Eligible to re-screen 4-weeks after completion of treatment
  • Unwilling to discontinue the use of specified intra-vaginal products during the study including the following: vaginal probiotic suppositories, vaginal moisturizers, boric acid suppositories, pH balancing wipes, intravaginal gel, external vaginal itch relief cream, odor control sprays, vaginal steam products, vaginal cleansing douche, feminine/vaginal cleanser, vaginal preventive deodorant, gel/cream treatments for feminine odor
  • Orally administered probiotics for vaginal health. NOTE: Oral probiotics for non-vaginal conditions (e.g., gastrointestinal health) are permitted. Eligible to re-screen 1-week after discontinuing orally administered probiotics for vaginal health
  • Pregnant, breastfeeding or trying to conceive during the course of the study
  • Active abnormal uterine/vaginal bleeding
  • Receiving chronic oral therapy (excluding those for skin, eyes, nose, or inhaled) or have received such therapy within 4 weeks of screening
  • Surgery, immunotherapy, chemotherapy, radiation or biological cancer therapy within 30 days of enrollment and/or planned during the next 3 months
  • Allergy to any components of the supporting or ingredients in test formulation tablets/placebo
  • Active serious medical condition requiring current treatment including but not limited to: Cancer, diseases (lupus, rheumatoid arthritis, Crohn's disease), Chronic infections (e.g., , , ), Serious cardiac, liver, or kidney disease, Psychiatric conditions/substance use disorders,
  • Any condition which in the investigator's opinion may jeopardize the individual's safety or interfere with the ability to comply with the study
  • Lives in the state of Alaska, Louisiana, New Jersey or New York
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
200 participants (actual)

Study arms

  • Experimental
    VH-01 vaginal suppository tablet

    Participants will be instructed to take VH-01 vaginal suppository tablet (active product) as directed.

    Other: VH-01 vaginal suppository tablet

  • Placebo comparator
    Placebo vaginal suppository tablet

    Participants will be instructed to take the placebo vaginal suppository tablet as directed. The placebo vaginal suppositories do not contain active ingredients and are identical in appearance to the active product.

    Other: Placebo vaginal suppository tablet

Interventions

  • OtherVH-01 vaginal suppository tablet

    Participants will be instructed to take VH-01 Days 1, 4, 7, 14, and 21 of Month 1 and Days 1 and 14 of Months 2 and 3.

  • OtherPlacebo vaginal suppository tablet

    Participants will be instructed to take the placebo on Days 1, 4, 7, 14, and 21 of Month 1 and Days 1 and 14 of Months 2 and 3.

06

What researchers measure

Primary outcomes

  1. To evaluate user experience of VH-01 vaginal suppository vs. placebo.

    Self-reported rate of product acceptance to support vaginal health through month 3.

    Time frame: From enrollment through three complete menstrual cycles or approximately 3 months.

Secondary outcomes

  1. To evaluate attitudes and perceptions of VH-01 vaginal suppository usage vs. placebo.

    Self-reported change in perception of vaginal state through month 3 \[5-point Likert scale\].

    Time frame: From enrollment through three complete menstrual cycles or approximately 3 months.

  2. To evaluate health-related quality of life during the use of VH-01 vaginal suppository vs. placebo.

    Self-reported change in vaginal health-related quality of life through month 3 \[5-point Likert scale\].

    Time frame: From enrollment through three complete menstrual cycles or approximately 3 months.

Other outcomes

  1. To evaluate changes in self-perceived vaginal discomforts during the use of VH-01 vaginal suppository vs. placebo.

    Self-reported change in specific vaginal discomforts through month 3 \[10-point linear scale\].

    Time frame: From enrollment through three complete menstrual cycles or approximately 3 months.

07

Study locations

1 site
  • Citruslabs
    Santa Monica, California 90404, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2024 to primary completion in Jul 2024, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2024
First posted
Feb 1, 2024
StartActual
Jan 29, 2024
Primary completionActual
Jul 31, 2024
CompletionActual
Jul 31, 2024
Last update
May 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06236893
Lead sponsor
Seed Health
Responsible party
Sponsor
First posted
Feb 1, 2024
Start date
Jan 29, 2024
Primary completion
Jul 31, 2024
Completion
Jul 31, 2024
Last update
May 31, 2025

Study contacts

Dirk Gevers, PhD
study director

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion